Leveraging the Individualized Metabolic Surgery Score to Predict Weight Loss with Tirzepatide in Adults with Type 2 Diabetes and Obesity
Recommended Citation
Castaneda R, Sepulveda D, Rivera Gutierrez R, Villamarin J, Bechenati D, Espinosa MA, Verastegui A, Tama E, McNally AW, Bennett PK, Acosta A, and Hurtado Andrade MD. Leveraging the Individualized Metabolic Surgery Score to Predict Weight Loss with Tirzepatide in Adults with Type 2 Diabetes and Obesity. Diabetology 2026;7(1):10.
Document Type
Article
Publication Date
1-4-2026
Publication Title
Diabetology
Keywords
tirzepatide; type 2 diabetes; obesity
Abstract
Background/Objectives: Individuals with type 2 diabetes (T2D) achieve less total body weight loss (TBWL) with obesity medications compared to those without T2D. The individualized metabolic surgery (IMS) score, originally developed to predict T2D remission after bariatric surgery, inversely correlates with TBWL response to semaglutide. IMS reflects T2D severity, incorporating HbA1c and T2D duration and medication use. This study aims to evaluate TBWL with tirzepatide across IMS severity categories and identify predictors of response in a real-world cohort.
Methods: This retrospective analysis included 717 adults with T2D using tirzepatide for overweight or obesity within the Mayo Clinic Health System. Patients were stratified by IMS severity (mild, moderate, severe) and quartiles. Primary endpoint: TBWL% at 15 months. Secondary endpoints: categorical thresholds (≥5%, ≥10%, ≥15%, ≥20%) and predictors of TBWL%. Linear mixed-effects models and regression models were employed.
Results: At 15 months, TBWL was greater in mild versus severe IMS groups (14.8% vs. 11.0%, p = 0.015), with similar trends across quartiles. The proportion achieving ≥ 20% TBWL was nearly two-fold higher in mild versus severe IMS (27% vs. 14%, p = 0.03). Female sex independently predicted greater TBWL, whereas insulin use, higher T2D medication burden (particularly weight-promoting agents), and HbA1c > 7% were associated with less TBWL.
Conclusions: Tirzepatide produced clinically meaningful TBWL across all IMS categories, although TBWL declined with increasing IMS severity. Glycemic control and T2D medication use emerged as strong predictors of TBWL. The IMS score may serve as a practical tool to anticipate weight-loss trajectories, guide personalized treatment decisions, and inform patient counseling.
PubMed ID
Not assigned.
Volume
7
Issue
1
First Page
10
